Polymyalgia rheumatica and giant-cell arteritis

The Lancet

Volumn 372, Issue 9634, 2008, Pages 234-245

  Salvarani, Carlo ^a   Cantini, Fabrizio ^b   Hunder, Gene G ^c  

^a S MARIA NUOVA HOSPITAL   (Italy)

^b MISERICORDIA E DOLCE HOSPITAL   (Italy)

^c Mayo Clinic   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; AZATHIOPRINE; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; GLUCOCORTICOID; INFLIXIMAB; METHOTREXATE; METHYLPREDNISOLONE; PREDNISOLONE; PREDNISONE; PROTON PUMP INHIBITOR; VITAMIN D;

AORTA ARCH SYNDROME; AORTA DISSECTION; AVASCULAR NECROSIS; CATARACT; CEREBROVASCULAR ACCIDENT; CLAUDICATION; CLINICAL FEATURE; CLINICAL TRIAL; COMPUTED TOMOGRAPHIC ANGIOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; DIABETES MELLITUS; DIAGNOSTIC TEST; DIFFERENTIAL DISPLAY; DISEASE ASSOCIATION; DISEASE COURSE; DOSE RESPONSE; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG MEGADOSE; ENVIRONMENTAL FACTOR; FRACTURE; GASTROINTESTINAL HEMORRHAGE; GIANT CELL ARTERITIS; HEADACHE; HEREDITY; HUMAN; HYPERTENSION; INFECTION; JAW; LABORATORY TEST; LOW DRUG DOSE; MORBIDITY; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOGENESIS; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REVIEW; RHEUMATIC POLYMYALGIA; SCALP; SINGLE DRUG DOSE; SYNOVITIS; THORACIC AORTA ANEURYSM; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT; VISUAL IMPAIRMENT;

EID: 47349103031     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(08)61077-6     Document Type: Review

References (134)

1. Chuang T.-Y., Hunder G., Ilstrup D., and Kurland L. Polymyalgia rheumatica: a 10-year epidemiologic and clinical study. Ann Intern Med 97 (1982) 672-680
2. Healey L. Long-term follow-up of polymyalgia rheumatica: evidencefor synovitis. Semin Arthritis Rheum 13 (1984) 322-328
3. Bird H., Esselinckx W., Dixon A., Mowat A., and Wood P. An evaluation of criteria for polymyalgia rheumatica. Ann Rheum Dis 38 (1979) 434-439
4. Hunder G., Bloch D., Michel B., et al. The American College of Rheumatology 1990 criteria for the classification of giant cell (temporal) arteritis. Arthritis Rheum 33 (1990) 1122-1128
5. Rao K., Allen N., and Pincus T. Limitations of the 1990 American College of Rheumatology classification criteria in the diagnosis of vasculitis. Ann Intern Med 129 (1998) 345-352
6. Taylor-Gjevre R., Vo M., Shukla D., and Resch L. Temporal artery biopsy for giant cell arteritis. J Rheumatol 32 (2005) 1279-1282
7. Chakrabarty A., and Franks A. Temporal artery biopsy: is there any value in examining biopsies at multiple levels?. J Clin Pathol 53 (2000) 131-136
8. Boyev L., Miller N., and Green W. Efficacy of unilateral versus bilateral temporal artery biopsies for the diagnosis of giant cell arteritis. Am J Ophthalmol 128 (1999) 211-215
9. Hall J., Volpe N., Galetta S., Liu G., Syed N., and Balcer L. The role of unilateral temporal artery biopsy. Ophthalmology 110 (2003) 543-548
10. Achkar A., Lie J., Hunder G., O'Fallon W., and Gabriel S. How does previous corticosteroid treatment affect the biopsy findings in giant cell (temporal) arteritis?. Ann Intern Med 120 (1994) 987-992
11. Younge B., Cook B., Bartley G., Hodge D., and Hunder G. Initiation of glucocorticoid therapy: before or after temporal artery biopsy?. Mayo Clin Proc 79 (2004) 483-491
12. Smetana G., and Shmerling R. Does this patient have temporal arteritis?. JAMA 287 (2002) 92-101
13. Salvarani C., Cantini F., Boiardi L., and Hunder G. Polymyalgia rheumatica and giant-cell arteritis. N Engl J Med 347 (2002) 261-271
14. Salvarani C., Crowson C., O'Fallon W., Hunder G., and Gabriel S. Reappraisal of the epidemiology of giant cell arteritis in Olmsted County, Minnesota, over a fifty-year period. Arthritis Rheum 51 (2004) 264-268
15. Nordborg E., and Nordborg C. Giant cell arteritis: epidemiological clues to its pathogenesis and an update on its treatment. Rheumatology 42 (2003) 413-421
16. Gran J., and Myklebust G. The incidence of polymyalgia rheumatica and temporal arteritis in the county of Aust Agder, south Norway: a prospective study 1987-1994. J Rheumatol 24 (1997) 1739-1743
17. Salvarani C., Macchioni P., Zizzi F., et al. Epidemiologic and immunogenetic aspects of polymyalgia rheumatica and giant cell arteritis in Northern Italy. Arthritis Rheum 34 (1991) 351-356
18. Gonzalez-Gay M., Miranda-Filloy J., Lopez-Diaz M., et al. Giant cell arteritis in Northwestern Spain. A 25-year epidemiologic study. Medicine 86 (2007) 61-68
19. Chaudhry I., Shamsi F., Elzaridi E., Arat Y., Bosley T., and Riley F. Epidemiology of giant cell arteritis in an Arab population: a 22-year study. Br J Ophthalmol 91 (2007) 715-718
20. Kobayashi S., Yano T., Matsumoto Y., et al. Clinical and epidemiologic analysis of giant cell (temporal) arteritis from a nationwide survey in 1998 in Japan: the first government-supported nationwide survey. Arthritis Rheum 49 (2003) 594-598
21. Östberg G. On arteritis with special reference to polymyalgia arteritica. Acta Pathol Microbiol Scand (A) 237 suppl (1973) 1-59
22. Salvarani C., Gabriel S., O'Fallon W., and Hunder G. The incidence of giant cell arteritis in Olmsted County, Minnesota: apparent fluctuations in a cyclic pattern. Ann Intern Med 123 (1995) 192-194
23. Bas-Lando M., Breuer G., Berkun Y., Mates M., Sonnenblick M., and Nesher G. The incidence of giant cell arteritis in Jerusalem over a 25-year period: annual a seasonal fluctuations. Clin Exp Rheumatol 25 suppl 44 (2007) S15-S17
24. Nuenninghoff D., Hunder G., Christianson T., McClelland R., and Matteson E. Mortality of large-artery complication (aortic aneurysm, aortic dissection, and/or large-artery stenosis) in patients with giant cell arteritis. A population-based study over 50 years. Arthritis Rheum 48 (2003) 3532-3537
25. Salvarani C., Gabriel S., O'Fallon W., and Hunder G. Epidemiology of polymyalgia rheumatica in Olmsted County, Minnesota, 1970-1991. Arthritis Rheum 38 (1995) 369-373
26. Franzén P., Sutinen S., and Von Knorring J. Giant cell arteritis and polymyalgia rheumatica in a region of Finland: an epidemiologic, clinical and pathologic study, 1984-1988. J Rheumatol 19 (1992) 273-280
27. Smeeth L., Cook C., and Hall A. Incidence of diagnosed polymyalgia rheumatica and temporal arteritis in the United Kingdom, 1990-2001. Ann Rheum Dis 65 (2006) 1093-1098
28. Cantini F., Niccoli L., Storri L., et al. Are polymyalgia reumatica and giant cell arteritis the same disease?. Semin Arthrititis Rheum 33 (2004) 294-301
29. Gonzalez-Gay M. Giant cell arteritis and polymyalgia rheumatica: two different but often overlapping conditions. Semin Arthritis Rheum 33 (2004) 289-293
30. Blockmans D., De Ceuninck L., Vanderschueren S., Knockaert D., Mortelmans L., and Bobbaers H. Repetitive 18-fluorodeoxyglucose positron emission tomography in isolated polymyalgia rheumatica: a prospective study in 35 patients. Rheumatology (Oxford) 46 (2007) 672-677
31. Wilkinson I., and Russell R. Arteries of the head and neck in giant cell arteritis. A pathological study to show the pattern of arterial involvement. Arch Neurol 27 (1972) 378-391
32. Salvarani C., Giannini C., Miller D., and Hunder G. Giant cell arteritis: involvement of intracranial arteries. Arthritis Rheum 55 (2006) 985-989
33. Lie J. Illustrated histopathologic classification criteria for selected vasculitis syndromes. Arthritis Rheum 33 (1990) 1074-1087
34. Klein R., Campbell R., Hunder G., and Carney J. Skip lesions in temporal arteritis. Mayo Clin Proc 51 (1976) 504-510
35. Esteban M.-J., Font C., Hernandez-Rodriguez J., et al. Small-vessel vasculitis surrounding a spared temporal artery: clinical and pathologic findings in a series of twenty-eight patients. Arthritis Rheum 44 (2001) 1387-1395
36. Meliconi R., Pulsatelli L., Uguccioni M., et al. Leukocyte infiltration in synovial tissue from the shoulder of patients with polymyalgia rheumatica. Quantitative analysis and influence of corticosteroid treatment. Arthritis Rheum 39 (1996) 1199-1207
37. Elling P., Olsson A., and Elling H. Synchronous variations of the incidence of temporal arteritis and polymyalgia rheumatica in different regions of Denmark; association with epidemics of Mycoplasma pneumoniae infection. J Rheumatol 23 (1996) 112-119
38. Duhaut P., Bosshard S., and Ducroix J.-P. Is giant cell arteritis and infectious disease? Biological and epidemiological evidence. Presse Med 33 (2004) 1403-1408
39. Machado E., Gabriel S., Beard C., Michet C., O'Fallon W., and Ballard D. A population-based case-control study of temporal arteritis: evidence for an association between temporal arteritis and degenerative vascular disease?. Int J Epidemiol 18 (1989) 836-841
40. Duhaut P., Pinede L., Demolombe-Rague S., et al. Giant cell arteritis and cardiovascular risk factors. A multicenter, prospective case-control study. Arthritis Rheum 41 (1998) 1960-1965
41. Gonzalez-Gay M., Pineiro A., Gomez-Gigirey A., et al. Influence of traditional risk factors of atherosclerosis in the development of severe ischemic complications in giant cell arteritis. Medicine 83 (2004) 342-347
42. Salvarani C., Boiardi L., Mantovani V., et al. HLA-DRB1 alleles associated with polymyalgia rheumatica in northern Italy: correlation with disease severity. Ann Rheum Dis 58 (1999) 303-308
43. Gonzalez-Gay M., Amoli M., Garcia-Porrua C., and Ollier W. Genetic markers of disease. Susceptibility and severity in giant cell arteritis and polymyalgia rheumatica. Semin Arthritis Rheum 33 (2003) 38-48
44. Weyand C., and Goronzy J. Medium- and large-vessel vasculitis. N Engl J Med 349 (2003) 160-169
45. Weyand C., Wei M.-A., Pryshchep O., Groschel S., Bernardino R., and Goronzy J. Vascular dendritic cells in giant cell arteritis. Ann NY Acad Sci 1062 (2005) 195-208
46. Lozano E., Segarra M., Garcia-Martinez A., Hernanadez-Rodriguez J., and Cid M. Imatinib mesylate inhibits in vitro and ex vivo biologic responses related to vascular occlusion in giant cell arteritis. Ann Rheum Dis (2007) 10.1136/ard.2007.070805 published online June 21.
47. Weyand C., Hicok K., Hunder G., and Goronzy J. Tissue cytokine patterns in patients with polymyalgia rheumatica and giant cell arteritis. Ann Intern Med 121 (1994) 484-491
48. Salvarani C., Cimino L., Macchioni P., et al. Risk factors for visual loss in an Italian population-based cohort of patients with giant cell arteritis. Arthritis Rheum 53 (2005) 293-297
49. Hernandez-Rodriguez J., Segarra M., Vilardell C., et al. Elevated production of interleukin-6 is associated with a lower incidence of disease-related ischemic events in patients with giant cell arteritis: angiogenic activity of interleukin-6 as a potential protective mechanism. Circulation 107 (2003) 2428-2434
50. Cid M., Hernandez-Rodriguez J., Esteban M., et al. Tissue and serum angiogenic activity is associated with low prevalence of ischemic complications in patients with giant cell arteritis. Circulation 106 (2002) 1664-1671
51. Salvarani C., Macchioni P., Tartoni P., et al. Polymyalgia rheumatica and giant cell arteritis: a 5-year epidemiologic and clinical study in Reggio Emilia, Italy. Clin Exp Rheumatol 5 (1987) 205-215 et-al.
52. Calamia K., and Hunder G. Giant cell arteritis (temporal arteritis) presenting as fever of undetermined origin. Arthritis Rheum 24 (1981) 1414-1418
53. Gonzalez-Gay M., Garcia-Porrua C., Amor-Dorado J., and Llorca J. Fever in biopsy proven giant cell arteritis: clinical implications in a defined population. Arthritis Rheum 51 (2004) 652-655
54. Salvarani C., Gabriel S., and Hunder G. Distal extremity swelling with pitting edema in polymyalgia rheumatica: report of nineteen cases. Arthritis Rheum 39 (1996) 73-80
55. Salvarani C., Cantini F., Olivieri I., and Hunder G. Polymyalgia rheumatica: a disorder of extraarticular synovial structures?. J Rheumatol 26 (1999) 517-521
56. Salvarani C., Cantini F., Macchioni L., et al. Distal musculoskeletal manifestations in polymyalgia rheumatica. A prospective follow-up study. Arthritis Rheum 41 (1998) 1221-1226
57. Calamia K., and Hunder G. Clinical manifestations of giant cell (temporal) arteritis. Clin Rheum Dis 6 (1980) 389-403
58. Gonzalez-Gay M., Barros S., Lopez-Diaz M., Garcia-Porrua C., Sanchez-Andrade A., and Llorca J. Giant cell arteriris: disease patterns of clinical presentation in a series of 240 patients. Medicine (Baltimore) 84 (2005) 269-276
59. Salvarani C., Gabriel S., Gertz M., Bjornsson J., Li C.-Y., and Hunder G. Primary systemic amyloidosis presenting as giant cell arteritis and polymyalgia rheumatica. Arthritis Rheum 37 (1994) 1621-1626
60. Aiello P., Trautmann J., McPhee T., Kunselman A., and Hunder G. Visual prognosis in giant cell arteritis. Ophthalmology 100 (1993) 550-556
61. Gonzalez-Gay M., Garcia-Porrua C., Llorca J., et al. Visual manifestations of giant cell arteritis: trends and clinical spectrum in 161 patients. Medicine (Baltimore) 79 (2000) 283-292
62. Salvarani C., and Hunder G. Musculoskeletal manifestations in a population-based cohort of patients with giant cell arteritis. Arthritis Rheum 42 (1999) 1259-1266
63. Cantini F., Salvarani C., Olivieri I., et al. Remitting seronegative symmetrical synovitis with pitting oedema (RS3PE) syndrome: a prospective follow-up and magnetic resonance imaging study. Ann Rheum Dis 58 (1999) 230-236
64. Gonzalez-Gay M., Garcia-Porrua C., Amor-Dorado J., and Lorca J. Giant cell arteritis without clinically evident vascular involvement in a defined population. Arthritis Rheum 51 (2004) 274-277
65. Hayreh S., Podhajsky P., and Zimmerman B. Occult giant cell arteritis: ocular manifestations. Am J Ophthalmol 125 (1998) 521-526
66. Bongartz T., and Matteson E. Large-vessel involvement in giant cell arteritis. Curr Opin Rheumatol 18 (2006) 10-17
67. Gonzalez-Gay M., Garcia-Porrua C., Pineiro A., Pego-Reigosa R., Llorca J., and Hunder G. Aortic aneurysm and dissection in patients with biopsy-proven giant cell arteritis from northwestern Spain: a population-based study. Medicine (Baltimore) 83 (2004) 335-341
68. Le Hello C., Lévesque H., Jeanton M., et al. Lower limb giant cell arteritis and temporal arteritis : followup of 8 cases. J Rheumatol 28 (2001) 1407-1412
69. Caselli R., Hunder G., and Whisnant J. Neurologic disease in biopsy-proven giant cell (temporal) arteritis. Neurology 38 (1988) 352-359
70. Caselli R., Daube J., Hunder G., and Whisnant J. Peripheral neuropathic syndromes in giant cell (temporal) arteritis. Neurology 38 (1988) 685-689
71. Gonzalez-Gay M., Blanco R., Rodriguez-Valverde V., et al. Permanent visual loss and cerebrovascular accidents in giant cell arteritis: predictors and response to treatment. Arthritis Rheum 41 (1998) 1497-1504
72. Larson T., Hall S., Hepper N., and Hunder G. Respiratory tract symptoms as a clue to giant cell arteritis. Ann Intern Med 101 (1984) 594-597
73. Valstar M., Terpstra W., and de Jong R. Pericardial and pleural effusion in giant cell arteritis. Am J Med 114 (2003) 708-709
74. Lie J., Failoni D., and Davis Jr. D. Temporal arteritis with giant cell aortitis, coronary arteritis, and myocardial infarction. Arch Pathol Lab Med 110 (1986) 857-860
75. Bajocchi G., Zamorani G., Cavazza A., et al. Giant-cell arteritis of the female genital tract associated with occult arteritis and FDG-PET evidence of large vessel vasculitis. Clin Exp Rheumatol 25 suppl 44 (2007) S36-S39
76. Kariv R., Sidi Y., and Gur H. Systemic vasculitis presenting as a tumorlike lesion. Four case reports and an analysis of 79 reported cases. Medicine (Baltimore) 79 (2000) 349-359
77. Luzar M., Whisler R., and Hunder G. Syndrome of inappropriate secretion of antidiruetic hormone in association with temporal arteritis. J Rheumatol 9 (1982) 957-960
78. Lee C., Su W., and Hunder G. Dysarthria associated with giant cell arteritis. J Rheumatol 26 (1999) 931-932
79. Cantini F., Salvarani C., Olivieri I., et al. Erythrocyte sedimentation rate and C-reactive protein in the evaluation of disease activity and severity in polymyalgia rheumatica: a prospective follow-up study. Semin Arthritis Rheum 30 (2000) 17-24
80. Salvarani C., and Hunder G. Giant cell arteritis with low erythrocyte sedimentation rate: frequency of occurrence in a population-based study. Arthritis Rheum 45 (2001) 140-145
81. Hayreh S., Podhajsky P., Raman R., and Zimmerman B. Giant cell arteritis: validity and reliability of various diagnostic criteria. Am J Ophthalmol 123 (1997) 285-296
82. Weyand C., Fulbright J., Evans J., Hunder G., and Goronzy J. Corticosteroid requirements in polymyalgia rheumatica. Arch Intern Med 159 (1999) 577-584
83. Salvarani C., Cantini F., Niccoli L., et al. Acute phase response reactants and the risk of developing relapse/recurrence in polymyalgia rheumatica: a prospective follow up study. Arthritis Rheum 53 (2005) 33-38
84. Lopez-Hoyos M., de Alegria C.R., Blanco R., et al. Clinical utility of anti-CCP antibodies in the differential diagnosis of elderly-onset rheumatoid arthritis and polymyalgia rheumatica. Rheumatology 43 (2004) 655-657
85. O'Duffy J., Wahner H., and Hunder G. Joint imaging in polymyalgia rheumatica. Mayo Clin Proc 51 (1976) 519-524
86. Salvarani C., Cantini F., Olivieri I., et al. Proximal bursitis in active polymyalgia rheumatica. Ann Intern Med 27 (1997) 27-31
87. Cantini F., Salvarani C., Olivieri I., et al. Shoulder ultrasonography in the diagnosis of polymyalgia rheumatica: a case-control study. J Rheumatol 28 (2001) 1049-1055
88. Cantini F., Niccoli L., Nannini C., et al. Inflammatory changes of hip synovial structures in polymyalgia reumatica. Clin Exp Rheumatol 23 (2005) 462-468
89. Cantini F., Salvarani C., Olivieri I., et al. Inflamed shoulder structures in polymyalgia rheumatica with normal erythrocyte sedimentation rate. Arthritis Rheum 44 (2001) 1155-1159
90. Salvarani C., Silingardi M., Ghirarduzzi A., et al. Is duplex ultrasonography useful for the diagnosis of giant cell arteritis?. Ann Intern Med 137 (2002) 232-238
91. Karassa F., Matsagas M., Schmidt W., and Ioannidis J. Meta-analysis: test performance of ultrasonography for giant cell arteritis. Ann Intern Med 142 (2005) 359-369
92. Bley T., Weiben O., Uhl M., et al. Assessment of the cranial involvement pattern of giant cell arteritis with 3T magnetic resonance imaging. Arthritis Rheum 52 (2005) 2470-2477
93. Stanson A. Imaging findings in extracranial (giant cell) temporal arteritis. Clin Exp Rheumatol 18 suppl 20 (2001) S43-S48
94. Schmidt W., Natusch A., Möller D., Vorpahl K., and Gromnica-Ihle E. Involvement of peripheral arteries in giant cell arteritis: a color Doppler sonography study. Clin Exp Rheumatol 20 (2002) 309-318
95. Blockmans D., de Ceuninck L., Vanderschueren S., Knockaert D., Mortelmans L., and Bobbaers H. Repetitive 18F-fluorodeoxyglucose positron emission tomography in giant cell arteritis: a prospective study of 35 patients. Arthritis Rheum 55 (2006) 131-137
96. Gonzalez-Gay M., Garcia-Porrua C., Salvarani C., Olivieri I., and Hunder G. The spectrum of conditions mimicking polymyalgia rheumatica in Northwestern Spain. J Rheumatol 27 (2000) 2179-2184
97. McCarty D., O'Duffy J., Pearson L., and Hunter J. Remitting seronegative symmetrical synovitis with pitting edema. RS3PE syndrome. JAMA 254 (1985) 2763-2767
98. Olivieri I., Salvarani C., and Cantini F. Remitting distal extremity swelling with pitting edema: a distinct syndrome or a clinical feature of different inflammatory rheumatic diseases?. J Rheumatol 24 (1997) 249-252
99. Olivieri I., Garcia-Porrua C., Padula A., Cantini F., Salvarani C., and Gonzalez-Gay M. Late onset spondyloarthritis presenting with polymyalgia rheumatica features: description of 7 cases. Rheumatology Int 27 (2007) 927-933
100. Pego-Reigosa J., Rodriguez-Rodriguez M., Hurtado-Hernandez Z., et al. Calcium pyrophosphate deposition disease mimicking polymyalgia rheumatica: a prospective followup study of predictive factors for this condition in patients presenting with polymyalgia symptoms. Arthritis Rheum 53 (2005) 931-938
101. Hopkinson N., Shawe D., and Gumpel J. Polymyositis, not polymyalgia rheumatica. Ann Rheum Dis 50 (1991) 321-322
102. Niccoli L., Salvarani C., Baroncelli G., Padula A., Olivieri I., and Cantini F. Renal cell carcinoma mimicking polymyalgia rheumatica. Clues for a correct diagnosis. Scand J Rheumatol 31 (2002) 103-106
103. Churcill M., Geraci H., and Hunder G. Musculoskeletal manifestations of bacterial endocarditis. Ann Intern Med 87 (1977) 754-759
104. Pipitone N., and Salvarani C. Are steroids alone sufficient for the treatment of giant cell arteritis?. Best Pract Res Clin Rheumatol 19 (2005) 277-292
105. Hayreh S., Zimmerman B., and Kardon R. Visual improvement with corticosteroid therapy in giant cell arteritis. Report of a large study and review of literature. Acta Ophthalmol Scand 80 (2002) 355-367
106. Mazlumzadeh M., Hunder G., Easley K., et al. Treatment of giant cell arteritis using induction therapy with high-dose glucocorticoids: a double-blind, placebo-controlled, randomized prospective clinical trial. Arthritis Rheum 54 (2006) 3310-3318
107. Chevalet P., Barrier J., Pottier P., et al. A randomized, multicenter, controlled trial using intravenous pulses of mrthylprednisolone in the initial treatment of simple forms of giant cell arteritis: a one year followup study of 164 patients. J Rheumatol 27 (2000) 1484-1491
108. Hunder G., Sheps S., Allen G., and Joyce J. Daily and alternate-day corticosteroid regimens in treatment of giant cell arteritis: comparison in a prospective study. Ann Intern Med 82 (1975) 613-618
109. Andersson R., Malmvall B.-E., and Bengtsson B.-A. Long-term corticosteroid treatment in giant cell arteritis. Acta Med Scand 220 (1986) 465-469
110. Proven A., Gabriel S., Orces C., O'Fallon W., and Hunder G. Glucocorticoid therapy in giant cell arterits: duration and adverse outcomes. Arthritis Rheum 49 (2003) 703-708
111. Jover J., Hernandez-Garcia C., Morado I., Vargas E., Banares A., and Fernandez-Gutierrez B. Combined treatment of giant-cell arteritis with methotrexate and prednisone: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 134 (2001) 106-114
112. Hoffman G., Cid M., Hellmann D., et al. A multicenter, randomized, double-blind, placebo-controlled trial of adjuvant methotrexate treatment for giant cell arteritis. Arthritis Rheum 46 (2002) 1309-1318
113. Weyand C., Fulbright J., Hunder G., Evans J., and Goronzy J. Treatment of giant cell arteritis: interleukin-6 as a biologic marker of disease activity. Arthritis Rheum 43 (2000) 1041-1048
114. Recommendations for the prevention and treatment of glucocorticoid-induced osteoporosis. 2001 update. American College of Rheumatology Ad Hoc Committee on Glucocorticoid-Induced Osteoporosis. Arthritis Rheum 44 (2001) 1496-1503
115. Sambrook P. How to prevent steroid induced osteoporosis. Ann Rheum Dis 64 (2005) 176-178
116. Spiera R., Mitnick H., Kupersmith M., et al. A prospective, double-blind, randomized, placebo controlled trial of methotrexate in the treatment of giant cell arteritis (GCA). Clin Exp Rheumatol 19 (2001) 495-501
117. Mahr A., Jover J., Spiera R., et al. Adjunctive methotrexate for treatment of giant cell arteritis. An individual patient data meta-analysis. Arthritis Rheum 56 (2007) 2789-2797
118. De Silva M., and Hazleman B. Azathioprine in giant cell arteritis/polymyalgia rheumatica: a double-blind study. Ann Rheum Dis 45 (1986) 136-138
119. Hoffman G., Cid M., Rendt-Zagar K., et al. Infliximab for maintenance of glucocorticosteroid-induced remission of giant cell arteritis: a randomized trial. Ann Intern Med 146 (2007) 621-630
120. Hernandez-Rodriguez J., Segarra M., Vilardell C., et al. Tissue production of pro-inflammatory cytokines (IL-1beta, TNFalpha and IL-6) correlates with the intensity of the systemic inflammatory response and with corticosteroid requirements in giant-cell arteritis. Rheumatology (Oxford) 43 (2004) 294-301
121. Cantini F., Niccoli L., Salvarani C., Padula A., and Olivieri I. Treatment of longstanding active giant cell arteritis with infliximab: report of four cases. Arthritis Rheum 44 (2001) 2933-2935
122. Nesher G., Berkun Y., Mates M., Baras M., Rubinow A., and Sonnenblick M. Low-dose aspirin and prevention of cranial ischemic complications in giant cell arteritis. Arthritis Rheum 50 (2004) 1332-1337
123. Lee M., Smith S., Galor A., and Hoffman G. Antiplatelet and anticoagulant therapy in patients with giant cell arteritis. Arthritis Rheum 54 (2006) 3306-3309
124. Weyand C., Kaiser M., Yang H., Younge B., and Goronzy J. Therapeutic effects of acetylsalicylic acid in giant cell arteritis. Arthritis Rheum 46 (2002) 457-466
125. Salvarani C., Cantini F., Boiardi L., and Hunder G. Polymyalgia rheumatica. Best Pract Res Clin Rheumatol 18 (2004) 705-722
126. Kremers H., Reinalda M., Crowson C., Zinsmeister A., Hunder G., and Gabriel S. Relapse in a population based cohort of patients with polymyalgia rheumatica. J Rheumatol 32 (2005) 65-73
127. Ayoub W., Franklin C., and Torretti D. Polymyalgia rheumatica: duration of therapy and long-term outcome. Am J Med 79 (1985) 309-315
128. Gabriel S., Sunku J., Salvarani C., O'Fallon W., and Hunder G. Adverse outcomes of anti-inflammatory therapy among patients with polymyalgia rheumatica. Arthritis Rheum 40 (1997) 1873-1878
129. Caporali R., Cimmino M., Ferraccioli G., et al. Prednisone plus methotrexate for polymyalgia rheumatica: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 141 (2004) 493-500
130. Salvarani C., Cantini F., Niccoli L., et al. Treatment of refractory polymyalgia rheumatica with infliximab: a pilot study. J Rheumatol 30 (2003) 760-763
131. Catanoso M., Macchioni P., Boiardi L., Pipitone N., and Salvarani C. Treatment of refractory polymyalgia rheumatica with etanercept: an open pilot study. Arthritis Rheum 57 (2007) 1514-1519
132. Salvarani C., Macchioni P., Manzini C., et al. Infliximab plus prednisone or placebo plus prednisone for the initial treatment of polymyalgia rheumatica. A randomized trial. Ann Intern Med 146 (2007) 631-639
133. Strand V., and Yazici Y. Interleukin-6 inhibition. Tolerability profile and clinical implications. Bull NYU Hosp JT Dis 65 suppl 1 (2007) S21-S24
134. Davis P., Nadler S., Stetsko D., and Suchard S. Abatacept modulates human dendritic cell-stimulated T-cell proliferation and effector function independent of IDO induction. Clin Immunol 126 (2008) 38-47